About Spyre Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://spyre.com/
Frequently Asked Questions
What is the 52-week range for SYRE?
The 52-week high is $110.175 and the 52-week low is $15.86.
What is the P/E ratio for SYRE?
The P/E ratio data is currently unavailable.
What is the dividend yield for SYRE?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -24.32%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -22158.54%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.55.
Analyst Recommendation Trends
Wall Street analyst consensus for SYRE over the last few months:
Latest SYRE News
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase a
Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls
Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls
JP Morgan Initiates Coverage On Spyre Therapeutics with Overweight Rating, Announces Price Target of $110
JP Morgan analyst Hardik Parikh initiates coverage on Spyre Therapeutics (NASDAQ:SYRE) with a Overweight rating and announces Price Target of $110.
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target
BTIG analyst Julian Harrison reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Buy and maintains $121 price target.
Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday
U.S. stocks rose as Nasdaq gained 100+ points; HPE jumped 5.1% on stronger networking guidance and a Vultr AI rack order.
What Does Spyre Therapeutics (SYRE) Part A Trial Success Mean For Ulcerative Colitis?
Spyre Therapeutics (NasdaqGS:SYRE) reported positive 12-week induction data from Part A of its Phase 2 SKYLINE trial for SPY003. The Phase 2 study delivered clinical proof-of-concept for SPY003, the firm's anti-IL-23 therapy for ulcerative colitis. Management also reported biological proof-of-concept for all three immunology mechanisms in Spyre Therapeutics' inflammatory bowel disease portfolio. The positive 12-week SKYLINE Part A results for SPY003 and Spyre's IBD mechanisms deserve to be...
Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight
The launch of emerging therapies such as ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib (TAK-279; Takeda), Sonelokimab (MoonLake Immunotherapeutics), Vunakizumab (Suzhou Suncadia), SPY 072 (Spyre Therapeutics), PN-881 (Protagonist Therapeutics), and others is expected to significantly reshape the Psoriatic Arthritis (PsA) market by expanding treatment options and addressing unmet needs among patients with inade
Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests
On September 8, Spyre Therapeutics (NASDAQ:SYRE) announced that SPY003, its anti-IL-23 antibody, hit its primary endpoint in Part A of the Phase 2 SKYLINE trial, posting a 10.0-point reduction in Robart’s Histopathology Index score at Week 12 with a p-value below 0.0001. That result matters because it closes out a run of three straight readouts. […]
Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It?
Spyre Therapeutics, Inc. (NASDAQ:SYRE) reported September 8 results from 44 patients with moderately to severely active ulcerative colitis in the open-label Part A of the Phase 2 SKYLINE trial. At week 12, the mean Robarts Histopathology Index, a measure of tissue inflammation, declined by 10 points. Clinical remission, measured by the modified Mayo Score, was […]
Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Spyre Therapeutics, Inc. (SYRE) Citigroup's Biopharma Back to School Summit 2026 September 9, 2026 10:00 AM EDTCompany ParticipantsCameron Turtle - CEO...
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study
SYRE's SPY003 posts positive phase II UC data, strengthening Spyre's multi-mechanism IBD strategy.
Wedbush Reiterates Outperform on Spyre Therapeutics, Maintains $123 Price Target
Wedbush analyst David Nierengarten reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and maintains $123 price target.
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
SPY003 met its primary endpoint with a statistically significant reduction of 10.0 points (p<0.0001) from baseline at Week 12 in Robart’s Histopathology Index (RHI) score Secondary endpoints included clinical remission by modified Mayo Score of 20% and endoscopic improvement of 30% SPY003 was well tolerated with a safety profile consistent with the IL-23 class SKYLINE Part A has demonstrated potential best-in-class results for SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23); SKYL
Spyre's SPY003 Met Its Primary Endpoint
SPY003 met its primary endpoint with a statistically significant reduction of 10.0 points (p<0.0001) from baseline at Week 12 in Robart’s Histopathology Index (RHI) score Secondary endpoints included clinical
Spyre Therapeutics to Participate in Upcoming September Investor Conferences
WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that management will participate in the following upcoming investor conferences: Event: Citi 2026 BioPharma Back to School Conference – New YorkDate:
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?
Spyre Therapeutics (SYRE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-02 | King-Jones Heidy | -400 | - | - |
| 2026-09-02 | King-Jones Heidy | -400 | $90 | $36,000 |
| 2026-09-02 | King-Jones Heidy | +400 | $14.5 | $5,800 |
| 2026-09-02 | Burrows Scott L | -18,232 | $89.35 | $1,629,029 |
| 2026-09-01 | King-Jones Heidy | -27,999 | - | - |
| 2026-09-01 | King-Jones Heidy | -400 | $89.38 | $35,752 |
| 2026-09-01 | King-Jones Heidy | -6,206 | $88.17 | $547,183 |
| 2026-09-01 | King-Jones Heidy | -16,548 | $87.2 | $1,442,986 |
| 2026-09-01 | King-Jones Heidy | -4,845 | $86.4 | $418,608 |
| 2026-09-01 | King-Jones Heidy | +27,999 | $14.5 | $405,986 |
| 2026-09-01 | Burrows Scott L | -7,500 | - | - |
| 2026-09-01 | Burrows Scott L | -200 | $89.04 | $17,808 |
| 2026-09-01 | Burrows Scott L | -2,016 | $88.03 | $177,468 |
| 2026-09-01 | Burrows Scott L | -4,384 | $87.11 | $381,890 |
| 2026-09-01 | Burrows Scott L | -900 | $86.25 | $77,625 |
| 2026-09-01 | Burrows Scott L | +7,500 | $14.5 | $108,750 |
| 2026-09-01 | Turtle Cameron | -400 | $89.07 | $35,628 |
| 2026-09-01 | Turtle Cameron | -3,700 | $88.06 | $325,822 |
| 2026-09-01 | Turtle Cameron | -8,400 | $87.15 | $732,060 |
| 2026-09-01 | Turtle Cameron | -2,500 | $86.36 | $215,900 |
| 2026-08-07 | Albers Jeffrey W. | -5,000 | - | - |
| 2026-08-07 | Albers Jeffrey W. | -10,000 | $104.68 | $1,046,800 |
| 2026-08-07 | Albers Jeffrey W. | -8,000 | $104.38 | $835,040 |
| 2026-08-07 | Albers Jeffrey W. | -5,000 | $104.47 | $522,350 |
| 2026-08-07 | Albers Jeffrey W. | +5,000 | $10.39 | $51,950 |
| 2026-08-03 | Burrows Scott L | -7,500 | - | - |
| 2026-08-03 | Burrows Scott L | -100 | $97.1 | $9,710 |
| 2026-08-03 | Burrows Scott L | -2,300 | $96.3 | $221,490 |
| 2026-08-03 | Burrows Scott L | -5,100 | $95.21 | $485,571 |
| 2026-08-03 | Burrows Scott L | +7,500 | $14.5 | $108,750 |
| 2026-08-03 | Turtle Cameron | -16 | $97.46 | $1,559 |
| 2026-08-03 | Turtle Cameron | -1,392 | $96.82 | $134,773 |
| 2026-08-03 | Turtle Cameron | -5,635 | $95.93 | $540,566 |
| 2026-08-03 | Turtle Cameron | -7,157 | $95.1 | $680,631 |
| 2026-08-03 | Turtle Cameron | -800 | $93.97 | $75,176 |
| 2026-07-01 | Burrows Scott L | -7,500 | - | - |
| 2026-07-01 | Burrows Scott L | -1,725 | $88.37 | $152,438 |
| 2026-07-01 | Burrows Scott L | -5,775 | $87.55 | $505,601 |
| 2026-07-01 | Burrows Scott L | +7,500 | $14.5 | $108,750 |
| 2026-07-01 | Sloan Sheldon | -8,334 | - | - |
| 2026-07-01 | Sloan Sheldon | -1,834 | $88.34 | $162,016 |
| 2026-07-01 | Sloan Sheldon | -6,500 | $87.52 | $568,880 |
| 2026-07-01 | Sloan Sheldon | +8,334 | $27.46 | $228,852 |
| 2026-07-01 | Turtle Cameron | -590 | $88.91 | $52,457 |
| 2026-07-01 | Turtle Cameron | -4,234 | $88.12 | $373,100 |
| 2026-07-01 | Turtle Cameron | -10,176 | $87.44 | $889,789 |
| 2026-06-25 | Burrows Scott L | -15,000 | - | - |
| 2026-06-25 | Burrows Scott L | -10,000 | $87.14 | $871,400 |
| 2026-06-25 | Burrows Scott L | -5,000 | $87.12 | $435,600 |
| 2026-06-25 | Burrows Scott L | +15,000 | $14.5 | $217,500 |
| 2026-06-23 | Fairmount Healthcare Fund II L.P. | -16,667 | - | - |
| 2026-06-23 | Fairmount Healthcare Fund II L.P. | -4,684,781 | $85.31 | $399,658,667 |
| 2026-06-23 | Fairmount Healthcare Fund II L.P. | +666,680 | - | - |
| 2026-06-22 | HENDERSON MICHAEL THOMAS | -20,000 | $100 | $2,000,000 |
| 2026-06-03 | Sloan Sheldon | -8,333 | - | - |
| 2026-06-03 | Sloan Sheldon | -8,333 | $75 | $624,975 |
| 2026-06-03 | Sloan Sheldon | +8,333 | $27.46 | $228,824 |
| 2026-06-01 | Turtle Cameron | -3,294 | $71.38 | $235,126 |
| 2026-06-01 | Turtle Cameron | -8,149 | $70.5 | $574,505 |
| 2026-06-01 | Turtle Cameron | -3,557 | $69.4 | $246,856 |
| 2026-06-01 | Burrows Scott L | -7,500 | - | - |
| 2026-06-01 | Burrows Scott L | -3,100 | $72.06 | $223,386 |
| 2026-06-01 | Burrows Scott L | -2,599 | $70.77 | $183,931 |
| 2026-06-01 | Burrows Scott L | -1,801 | $69.75 | $125,620 |
| 2026-06-01 | Burrows Scott L | +7,500 | $14.5 | $108,750 |
| 2026-05-27 | Milligan Sandra | +8,026 | - | - |
| 2026-05-27 | Fairmount Healthcare Fund II L.P. | +8,026 | - | - |
| 2026-05-27 | Albers Jeffrey W. | +8,026 | - | - |
| 2026-05-27 | HENDERSON MICHAEL THOMAS | +8,026 | - | - |
| 2026-05-27 | Stelzer Laurie | +8,026 | - | - |
| 2026-05-27 | McKenna Mark C. | +8,026 | - | - |
| 2026-05-08 | HENDERSON MICHAEL THOMAS | -19,269 | $75.35 | $1,451,919 |
| 2026-05-08 | HENDERSON MICHAEL THOMAS | -24,814 | $74.76 | $1,855,095 |
| 2026-05-08 | HENDERSON MICHAEL THOMAS | -33,513 | $73.72 | $2,470,578 |
| 2026-05-08 | HENDERSON MICHAEL THOMAS | -2,404 | $72.57 | $174,458 |
| 2026-05-01 | Sloan Sheldon | -78,333 | - | - |
| 2026-05-01 | Sloan Sheldon | -400 | $75.37 | $30,148 |
| 2026-05-01 | Sloan Sheldon | -5,059 | $74.6 | $377,401 |
| 2026-05-01 | Sloan Sheldon | -10,358 | $73.74 | $763,799 |
| 2026-05-01 | Sloan Sheldon | -12,777 | $72.94 | $931,954 |
| 2026-05-01 | Sloan Sheldon | -8,777 | $71.56 | $628,082 |
| 2026-05-01 | Sloan Sheldon | -19,656 | $70.61 | $1,387,910 |
| 2026-05-01 | Sloan Sheldon | -21,306 | $69.53 | $1,481,406 |
| 2026-05-01 | Sloan Sheldon | +78,333 | $27.46 | $2,151,024 |
| 2026-05-01 | Burrows Scott L | -12,500 | - | - |
| 2026-05-01 | Burrows Scott L | -12,500 | $71.37 | $892,125 |
| 2026-05-01 | Burrows Scott L | +12,500 | $14.5 | $181,250 |
| 2026-05-01 | Turtle Cameron | -300 | $74.96 | $22,488 |
| 2026-05-01 | Turtle Cameron | -1,700 | $74.23 | $126,191 |
| 2026-05-01 | Turtle Cameron | -3,100 | $73.14 | $226,734 |
| 2026-05-01 | Turtle Cameron | -1,000 | $71.76 | $71,760 |
| 2026-05-01 | Turtle Cameron | -3,600 | $70.77 | $254,772 |
| 2026-05-01 | Turtle Cameron | -5,300 | $69.54 | $368,562 |
| 2026-04-01 | Burrows Scott L | -7,500 | - | - |
| 2026-04-01 | Burrows Scott L | -1,300 | $49.98 | $64,974 |
| 2026-04-01 | Burrows Scott L | -6,200 | $49.21 | $305,102 |
| 2026-04-01 | Burrows Scott L | +7,500 | $14.5 | $108,750 |
| 2026-04-01 | Turtle Cameron | -2,656 | $49.92 | $132,588 |
| 2026-04-01 | Turtle Cameron | -12,344 | $49.2 | $607,325 |
| 2026-04-01 | Sloan Sheldon | -7,958 | - | - |
| 2026-04-01 | Sloan Sheldon | -7,958 | $50 | $397,900 |
| 2026-04-01 | Sloan Sheldon | +7,958 | $21.66 | $172,370 |
| 2026-03-03 | Burrows Scott L | -2,500 | - | - |
| 2026-03-03 | Burrows Scott L | -200 | $41.66 | $8,332 |
| 2026-03-03 | Burrows Scott L | -2,300 | $40.56 | $93,288 |
| 2026-03-03 | Burrows Scott L | +2,500 | $14.5 | $36,250 |
| 2026-03-02 | Turtle Cameron | -9,100 | $42.49 | $386,659 |
| 2026-03-02 | Turtle Cameron | -5,900 | $41.73 | $246,207 |
| 2026-02-02 | Turtle Cameron | -14,043 | $32.87 | $461,593 |
| 2026-02-02 | Turtle Cameron | -957 | $31.82 | $30,452 |
| 2026-01-21 | HENDERSON MICHAEL THOMAS | +63,227 | - | - |
| 2026-01-09 | Burrows Scott L | +140,000 | - | - |
| 2026-01-09 | Turtle Cameron | +528,000 | - | - |
| 2026-01-09 | Sloan Sheldon | +140,000 | - | - |
| 2026-01-09 | King-Jones Heidy | +140,000 | - | - |
| 2026-01-02 | Turtle Cameron | -100 | $32.39 | $3,239 |
| 2026-01-02 | Turtle Cameron | -2,191 | $31.79 | $69,652 |
| 2026-01-02 | Turtle Cameron | -12,709 | $30.47 | $387,243 |
| 2025-12-01 | Turtle Cameron | -4,005 | $29.83 | $119,469 |
| 2025-12-01 | Turtle Cameron | -10,995 | $28.73 | $315,886 |
| 2025-11-03 | Turtle Cameron | -16,845 | $23.66 | $398,553 |
| 2025-11-03 | Turtle Cameron | -28,155 | $23.13 | $651,225 |